WO2017030330A1 - Composition de formule liquide pour nourrissons contenant du lait de chèvre - Google Patents
Composition de formule liquide pour nourrissons contenant du lait de chèvre Download PDFInfo
- Publication number
- WO2017030330A1 WO2017030330A1 PCT/KR2016/008932 KR2016008932W WO2017030330A1 WO 2017030330 A1 WO2017030330 A1 WO 2017030330A1 KR 2016008932 W KR2016008932 W KR 2016008932W WO 2017030330 A1 WO2017030330 A1 WO 2017030330A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milk
- composition
- casein
- goat
- liquid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 239000007788 liquid Substances 0.000 title claims abstract description 52
- 235000020251 goat milk Nutrition 0.000 title abstract description 25
- 235000013350 formula milk Nutrition 0.000 title abstract description 6
- 235000013336 milk Nutrition 0.000 claims abstract description 55
- 210000004080 milk Anatomy 0.000 claims abstract description 55
- 102000011632 Caseins Human genes 0.000 claims abstract description 54
- 108010076119 Caseins Proteins 0.000 claims abstract description 54
- 239000008267 milk Substances 0.000 claims abstract description 51
- 235000018102 proteins Nutrition 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 102000009366 Alpha-s1 casein Human genes 0.000 claims abstract description 24
- 108050000244 Alpha-s1 casein Proteins 0.000 claims abstract description 24
- 239000005018 casein Substances 0.000 claims abstract description 23
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000021240 caseins Nutrition 0.000 claims abstract description 23
- 235000021247 β-casein Nutrition 0.000 claims abstract description 22
- 241000283707 Capra Species 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000003921 oil Substances 0.000 claims description 25
- 239000010779 crude oil Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000003925 fat Substances 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011707 mineral Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 210000002445 nipple Anatomy 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 26
- 230000001079 digestive effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 16
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 230000007815 allergy Effects 0.000 abstract description 5
- 210000000481 breast Anatomy 0.000 abstract description 4
- 238000005457 optimization Methods 0.000 abstract description 4
- 235000008476 powdered milk Nutrition 0.000 abstract description 4
- 235000019198 oils Nutrition 0.000 description 24
- -1 sphingomyelin Substances 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 16
- 229930195729 fatty acid Natural products 0.000 description 16
- 239000000194 fatty acid Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 235000020256 human milk Nutrition 0.000 description 15
- 210000004251 human milk Anatomy 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 108010046377 Whey Proteins Proteins 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 235000021119 whey protein Nutrition 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 238000000265 homogenisation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000008192 Lactoglobulins Human genes 0.000 description 4
- 108010060630 Lactoglobulins Proteins 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229920000223 polyglycerol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 235000021246 κ-casein Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108050001786 Alpha-s2 casein Proteins 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 235000019621 digestibility Nutrition 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010011469 Crying Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000020191 long-life milk Nutrition 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241001057184 Axion Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- XYAUIVRRMJYYHR-UHFFFAOYSA-N acetic acid;propane-1,2,3-triol Chemical class CC(O)=O.OCC(O)CO XYAUIVRRMJYYHR-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020189 fortified milk Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- FJWLWIRHZOHPIY-UHFFFAOYSA-N potassium;hydroiodide Chemical compound [K].I FJWLWIRHZOHPIY-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
Definitions
- the present invention relates to a liquid crude oil composition containing a goat's milk, and more particularly to a liquid crude oil composition excellent in improving the absorption and digestion of all infants by the mother's milk-friendly formulation.
- Formulated milk is one of the artificial nutrition methods for babies. It is formulated with breast milk by combining various ingredients to compensate for the milk's component defects and to have a composition similar to breast milk.
- Most of the formula products are commercialized products starting from a milk-derived product called cow's milk, but the current formula is somewhat different from the composition of the ideal breast milk.
- powdered milk powder which occupies most of the current formula market, it is necessary to precisely feed the nutrients designed when dissolved in liquid form for feeding and to feed infants.
- a problem is found in which the amount designed for acidic and temperature conditions is not fed correctly.
- liquid formulas for feeding at a uniform crude oil concentration do not significantly deviate from the level of general milk formulations in terms of nutritional components, and thus, it was difficult to attain the charging agent of formulas such as breast milking and proper nutrition.
- casein and whey proteins can be broadly classified. Casein is generally divided into ⁇ S1-casein, ⁇ S2-casein, ⁇ -casein, and ⁇ -casein, and whey proteins include various proteins but ⁇ Lactoglobulin and ⁇ -lactalbumin are major constituent proteins. Among them, ⁇ -casein is the main protein of breast milk, and it is easy to digest because it does not coagulate well under the action of stomach acid and makes a soft appearance.
- ⁇ -S1 casein is the main ingredient to form a curd is a component that is low in digestibility when excessive content is known as a component that is hardly contained in breast milk but contained in milk.
- ⁇ -S1 casein and ⁇ -casein there is still insufficient research on the overall breast milk prescription to solve allergens and digestive problems considering the effects of ⁇ -S1 casein and ⁇ -casein.
- the formula may be prepared in solid form or in liquid form, such as powder.
- protein, fat, carbohydrates, vitamins, and minerals are contained in the formula, which requires a lot of heat treatment such as preheating step for homogeneity and sterilization and sterilization to maintain microbial safety. During this process, inevitably physical and chemical protein denaturation occurs.
- Whey proteins which are known to be a major factor in the mechanism of protein thermal degeneration, are accompanied by denaturation and aggregation of the protein itself. This would include irreversible protein-protein interactions of covalent bonds and protein-protein interactions of non-covalent bonds, in which case disulfide bonds of ⁇ -lactoglobulin are typical. This can occur mainly by sulfhydryl oxidation or sulfidyl-disulfide exchange, and also disulfide bonds (S-S) included in cysteine and the like bind to ⁇ -lactoglobulin to form strong aggregates leading to precipitation.
- S-S disulfide bonds
- the problem to be solved by the present invention is to provide a liquid preparation composition excellent in digestion absorption and allergy reduction effect of infants with a composition close to the mother's milk.
- Another problem to be solved by the present invention is to provide a method for producing a liquid crude oil composition significantly improved over time stability and digestive absorption through process optimization.
- the present invention includes any one or more selected from the group consisting of goat-derived milks, milk powders, and proteins, and provides a liquid crude oil composition containing 5 to 40% by weight based on the total weight of the composition.
- the present inventors have found that, when the goat oil (goat milk) -derived product is contained in the liquid formula, the content of ⁇ S1-casein, which is a major protein that forms a curd, is low.
- the high content of ⁇ -casein, which keeps the curd soft, makes it surprising that infants are easily absorbed when ingested and have a remarkable effect on reducing allergy in babies sensitive to milk proteins, thus completing the present invention.
- Goat milk has a lower total casein content than milk and is relatively similar in composition to breast milk.
- the appearance of curd by goat's milk is known to be small and soft compared to milk, and the amount of curd precipitated in the stomach is also known to be very small at 2% for goat's milk compared to 10% of milk.
- casein of breast milk is known to be completely hydrolyzed while milk is known to be degraded to about 75 to 90%, and goat milk is about 95%, which is relatively more similar to breast milk.
- Goat milk is also known to contain a large amount of vitamins and minerals with good bioavailability and absorption, and is known to have better absorption of nutrients such as calcium, phosphorus, and manganese than milk.
- goat milk is relatively less ⁇ -lactoglobulin in goat milk than milk-based preparations, and goat milk is more advantageous than milk-derived preparations in stabilizing the liquid formulation composition.
- Goat milk also exhibits different properties compared to milk in fat content and composition.
- Goat milk fat particles are finer and more uniform than milk, and the content of intermediate chain fatty acid is high, so that the decomposition rate is fast.
- goat milk is generally known to have about 5 times higher digestibility than milk.
- the melting point of the fatty acid is low and the hydrolysis rate is fast, which improves the digestion characteristics. Therefore, less bile acid is required for digestion.
- goat milk is easy and quick to absorb digestion can be used more advantageously than milk intake for infants with immature gastrointestinal function.
- goat milk is rich in constituents such as nucleotides, sphingomyelin, and selenium, and improvement effects on atopy or allergy have been reported continuously.
- goat-derived milks, milk powders and proteins used in the present invention have a low content of ⁇ -S1 casein, which is present in a large amount of milk, so that the protein coagulates due to gastric acid and does not interfere with digestion.
- the goat-derived preparation is easy to digest because the curd itself is high because of the high content of ⁇ -casein similar to breast milk.
- casein composition of known milk is about 75% for ⁇ -casein and about 25% for ⁇ -casein, and does not include ⁇ S1-casein.
- the casein composition of milk is about 36% for ⁇ -casein, about 13% for ⁇ -casein, about 33% for ⁇ S1-casein, and about 18% for ⁇ S2-casein.
- the casein composition of ⁇ -casein is about 62.8%, ⁇ -casein is about 10.4%, ⁇ S1- casein is about 5.6%, ⁇ S2- casein is about 21.2%, ⁇ S1- casein, ⁇ - casein compared to breast milk [Hyo-Hee Kim, Young-Seo Park, Sung-Sik Yoon, Composition of Goat Milk and Its Food and Nutritional Significance, Vol. 46, No 2, pp. 121-126 (2014)]
- the average diameter of casein micelles of milk is 100 to 250nm
- the average diameter of casein micelles of goat's milk has been refined to about 80nm level, it is relatively easier to absorb digestion.
- the solid content of the liquid preparation oil composition may be included in 5 to 40% by weight, preferably 6 to 30% by weight, more preferably 7 to 25% by weight relative to the total weight of the composition.
- the solid content is less than 5% by weight, a deficiency of the nutrient is caused, and when it is more than 40% by weight, it leads to a decrease in phase stability and an excess of the nutrient.
- ⁇ S1-casein in the liquid crude oil composition may be included in 0.1 to 27% by weight, preferably 0.5 to 20% by weight, more preferably 1 to 15% by weight relative to the total weight of casein. If the ⁇ S1-casein content exceeds 27% by weight of the total casein problem occurs that exhibits adverse effects on the digestive absorption, such as the creation of a curd, it is practically very difficult to prepare the ⁇ S1-casein content less than 0.1% by weight in the liquid crude oil composition.
- ⁇ -casein in the liquid crude oil composition may be included in 40 to 80% by weight, preferably 45 to 65% by weight relative to the total weight of casein.
- the content of ⁇ -casein is less than 40% by weight of the total casein, the effect of softening the curd is hardly exhibited, and the production of more than 80% by weight thereof is very difficult to apply in reality.
- the liquid crude oil composition of the present invention may include any one or more selected from the group consisting of goat-derived milks, milk powders, and proteins.
- the goat-derived milk may include any one or more selected from the group consisting of sterilized milk (salt milk), sterilized milk, low fat milk, nonfat milk, and fortified milk
- goat milk powder may include skim milk powder and whole milk powder.
- Sweetened milk powder, and mixed milk powder, etc. may include any one or more selected from the group consisting of goat protein, goat protein, concentrated goat protein, isolated protein, whey protein, demineralized whey protein, whey protein isolate, whey isolate It may include any one or more selected from the group consisting of protein, goat milk protein, goat whey protein and the like.
- the liquid preparation oil composition of the present invention may contain a milk-derived component
- the content of ⁇ S1-casein in the composition is 0.1 to 27% by weight, preferably 1 to 20% by weight, more preferably, of the total casein content for breast emulsification.
- it may contain from 1 to 15% by weight of milk derived components, or may not contain at all.
- Liquid preparation oil composition of the present invention can be prepared through homogenization (homogenization) for the purpose of improving the digestive absorption and formulation stabilization through the finer particles.
- homogenization homogenization
- micronization and homogenization of the particles by an optimized homogeneous effect minimizes aggregation between composition particles that occur over time. This results in an effect of delaying the aggregation between the particles for a considerable time compared to the relatively large and non-uniform particles, so that the homogenized composition significantly improves the aggregation, separation, and precipitation phenomenon in the formulation.
- the micronization and homogenization of the particles not only have a great effect on the stabilization of the liquid preparation oil, but also are very effective in improving the digestive absorption ability nutritionally.
- the present invention proposes an appropriate homogeneous pressure for the homogeneous effect.
- the homogeneous pressure may be set to 100 to 600 bar, preferably 150 to 400 bar. If the homogeneous pressure is less than 100 bar, the homogeneous effect is insignificant, resulting in a large particle size and thus a nonuniform distribution, resulting in lack of phase stability. On the other hand, when the homogeneous pressure exceeds 600 bar, the particles become extremely fine and rather cause agglomeration between the particles, which leads to a sharp drop in stability over time.
- the liquid preparation oil composition may have a particle size of less than 0.5 ⁇ m 90% or more, preferably 95% or more.
- the liquid preparation oil composition of the present invention has a particle size refinement process having a distribution of 90% or more of the particle size of less than 0.5 ⁇ m in the final finished product stage in order to improve digestion absorption and phase stability, in addition to the milking of the nutritional components as described above. It can be prepared through.
- the liquid crude oil composition of the present invention may further include any one or more selected from the group consisting of emulsifiers, vitamins, fats and oils, and minerals.
- the liquid crude oil composition of the present invention may further add an emulsifier for emulsion dispersion stability during manufacture.
- Glycerin fatty acid esters may be used as the emulsifier, and the glycerine fatty acid esters are compounds in which fatty acids and glycerin or polyglycerol are esterified or derivatives thereof.
- the glycerin fatty acid esters are glycerin fatty acid esters, glycerin acetic acid fatty acid esters, glycerin lactic acid fatty acid esters, glycerin citric acid fatty acid esters, glycerin zucchini acid fatty acid esters, glycerin diacetyl tartrate fatty acid esters, glycerin acetate esters, polyglycerol fatty acid esters, and It may include any one or more selected from the group consisting of polyglycerol condensed ricinoleic acid ester.
- glycerin fatty acid ester, polyglycerol fatty acid ester, or a mixture thereof may be used as the emulsifier.
- the liquid crude oil composition of the present invention may further include a vitamin for enhancing the nutritional component.
- the vitamin is a fat-soluble vitamin including vitamins A, E, D and K; And water-soluble vitamins including vitamins B1, B2, B6, B12, C, pantothenic acid, niacin, folic acid, biotin, and the like.
- the liquid crude oil composition of the present invention may further include fats and oils to supply saturated fats, unsaturated fats, and essential fatty acids to infants.
- the fat or oil may include any one or more selected from the group consisting of soybean oil, canola oil, palm ole oil, palm oil, palm kernel oil, sunflower oil, brown rice oil, corn oil, and refined common oil.
- the mineral in the liquid crude oil composition of the present invention is mainly used as a nutritional source, it may be additionally included for stabilizing the crude oil.
- the mineral may include any one or more selected from the group consisting of calcium carbonate, potassium monophosphate, potassium diphosphate, potassium chloride, magnesium diphosphate, sodium hydrogencarbonate, zinc oxide, ferric pyrophosphate, manganese sulfate, potassium iodine, and the like. have.
- the composition of the present invention can further reduce the denaturation and coagulation by heat treatment of the protein by additionally containing minerals. Especially potassium monophosphate and potassium diphosphate are preferred for the pH buffering role of the preparation.
- the liquid preparation oil composition may be subjected to ultra high temperature (Ultra High Temperature, UHT) for the killing of microorganisms.
- UHT Ultra High Temperature
- the ultra high temperature short time heat treatment method is a treatment technology for preserving a liquid product by short and powerful heating at a temperature range of ultra high temperature within a short time.
- the liquid crude oil composition of the present invention contains a large amount of carbohydrates, fats, and proteins, and is a high-nutrition composition that is easy to breed microorganisms at room temperature and for a long time storage. Although there are differences depending on the raw materials added, there are a large amount of microorganisms as in general dairy products, and there are also heat resistant bacteria that survive at refrigeration temperature and heat resistant bacteria that do not die even at high temperature heat treatment. Therefore, the liquid preparation oil composition of the present invention is preferably subjected to ultra high temperature and short heat treatment in order to completely kill microorganisms. This is due to less protein denaturation compared to the conventional retort method, and taste, odor, discoloration, etc. are better than the retort method.
- the ultra high temperature short time heat treatment may be performed under sterilization conditions of 1 to 60 seconds, preferably 5 to 50 seconds at a temperature of 120 to 150 °C, preferably 125 to 140 °C.
- the ultra-high temperature short time sterilization is less than 120 °C or less than 1 second, the microbial killing effect is insignificant, and when it is more than 150 °C or more than 60 seconds, precipitates are generated due to thermal denaturation or worsening of phase stability due to thermal damage.
- the present invention (s1) is dissolved by adding any one or more selected from the group consisting of goat-derived milk, milk powder, and proteins to the dissolved fat or oil; (s2) homogenizing the mixture of step (s1) to 90% or more of particles having a particle size of less than 0.5 ⁇ m; (s3) It provides a method for preparing a liquid crude oil composition comprising the step of sterilizing the product of step (s2) by ultra-high temperature heat treatment.
- Step (s1) of the preparation method may be prepared by adding a fat-soluble vitamin, an emulsifier, or a mixture thereof in addition to the dissolved fat or oil.
- the production method may be prepared by additionally adding water-soluble vitamins, minerals, or mixtures thereof after cooling by adding water to the product after step (s1).
- the preparation method may further include a step of preheating the mixture before the step (s2) in order to increase the homogenization effect.
- the homogenization of step (s2) of the manufacturing method may be performed at a homogeneous pressure of 100 to 600 bar.
- the ultra-high short time heat treatment of step (s3) of the manufacturing method may be performed for 1 to 60 seconds at a temperature of 120 to 150 °C.
- the present invention provides a liquid preparation oil product filled with the liquid preparation oil composition in a plastic container having a fastening portion capable of directly fastening a feeding nipple.
- the fastening portion may be a spiral fastening portion may be used, a configuration that can be easily fastened to each other by turning the nipple or plastic container may be used.
- the liquid preparation oil product can be easily fed by the consumer without the need for a separate feeding bottle by using a plastic container of the nipple and direct fastening method, and dilutes the existing powdered milk to prevent microbial contamination that may occur when feeding. There is an advantage.
- the container may be a plastic container or glass bottle made of various materials such as high density polyethylene (HDPE), low density polyethylene (LDPE), polyethylene terephthalate (PET), polypropylene (PP), polyethylene (PE), or polycarbonate (PC).
- HDPE high density polyethylene
- LDPE low density polyethylene
- PET polyethylene terephthalate
- PP polypropylene
- PE polyethylene
- PC polycarbonate
- the liquid crude oil composition according to the present invention has a very good effect of improving the absorption and allergy reduction of infants and infants by containing a goat's milk-friendly formulation, and the stability and digestive absorption of the liquid crude formula over time through the process optimization is remarkably excellent.
- Figure 1 is a photograph showing the results of the artificial gastric juice added to Comparative Example 1 and Example 5 in Experimental Example 1.
- the milk component change used in this example is to adjust the ratio of ⁇ S1-casein and ⁇ -casein by using milk derivatives and goat milk derivatives alone or in combination according to the prescription to be designed for relative comparison between goat milk and milk. And other nutritional and stabilizing ingredients remained equal.
- the content of goat-derived skim milk powder is gradually increased in the liquid formula to reduce ⁇ S1-casein and to increase the composition of ⁇ -casein, which is compared with the conventional milk-derived use of skim milk powder.
- the preparation method of the Example composition in the liquid crude oil composition is quantitatively added fat-soluble vitamins, emulsifiers, lecithins and the like to the fats and oils dissolved completely at high temperature, and completely dissolved by high temperature stirring, and then in purified water of about 70 °C Stirring was started with a homomixer while slowly adding. After a certain period of time, while maintaining the temperature at about 40 °C while stirring, the goat-derived or milk-derived ingredients are mixed or added alone according to the prescription to be designed, and after a certain period of time to compare the whey protein powder, degreasing Milk powder, lactose and other pH regulators, dextrin and the like was added and stirred. After cooling by adding water, and then mixed with water-soluble vitamins and minerals to complete the stirring and completed through preheating, homogeneous, and ultra-high temperature heat treatment (UHT).
- UHT ultra-high temperature heat treatment
- Experimental Example 1 artificial gastric fluid addition experiments were conducted to each Example, and the digestion clinical evaluation of Experimental Example 2 was performed based on the experimental results.
- Example Comparative Example 1 Example 1 Example 2 Example 3 Example 4 Example 5 Edible mixture oil and fat (% by weight) 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 Glycerin fatty acid ester (% by weight 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Skim milk powder (% by weight) (milk derived) 4.5 3.6 2.7 1.8 0.9 - Skimmed milk powder (% by weight) (goat derived) - 0.9 1.8 2.7 3.6 4.5 Whey Protein Concentrate Powder (wt%) (goat derived) One One One One One One One One One One One One Lactose (wt%) (goat derived) 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 Purified water and others (% by weight) To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 ⁇ S1-casein ratio by weight of total casein (% by weight) 33 27 22 17 11 5.6 ⁇ -casein
- Examples of the present invention was confirmed that exhibiting better digestive absorption characteristics compared to Comparative Example 1 derived from conventional milk by properly designing the ratio of ⁇ S1 and ⁇ -casein compared to the conventional milk-derived formulations.
- Example ⁇ S1-casein ratio (% by weight) relative to total casein ⁇ -casein ratio relative to total casein (wt%) Digestive absorption clinical evaluation result Comparative Example 1 33 36 - Example 2 22 47 ⁇ Example 5 5.6 63 ⁇
- Example 5 showed better results than Example 2. That is, in Example 5, the digestion absorption index (stool state, constipation, crying due to indigestion) was the best.
- Examples 1 to 5 the liquid crude oil composition (Examples 1 to 5) of the present invention was compared with the casein protein derived from goat, According to the optimization of the ⁇ S1-casein and ⁇ -casein ratio was found to be relatively similar to breast milk, and as a result it was confirmed that the better digestive absorption characteristics compared to Comparative Example 1 derived from milk.
- the samples stored at ⁇ 20 ° C. were thawed to extract protein from milk (or product), and then centrifuged at 1000 g for 10 minutes to remove fat separated from the upper layer and used for measurement.
- the pretreated solution was added with 8 M urea, 165 mM Tris, 44 mM sodium citrate, 0.3% (v / v) aqueous solution of mercaptoethanol, and then passed through a 0.45 ⁇ m pore filter paper to separate proteins.
- This solution contains both fat-soluble casein protein and whey protein, and the filtered protein was analyzed by fast gradient HPLC with an AxION ® TOF mass spectrometer.
- aqueous 0.1% (v / v) trifluoroacetic acid solution and an aqueous 0.1% (v / v) acetonitrile solution was used as a mobile phase.
- a protein having a mass range of 1000-2000 m / z was detected with a Micromass Q-TOF mass spectrometer.
- the ⁇ , ⁇ , and ⁇ -casein protein peaks shown in the samples were quantified against the standard peaks extracted from milk, respectively.
- Clinical evaluations were conducted in children aged 3 to 15 months of age who were selected by voluntary participation. Thirty infants were fed two weeks each of Experimental Product 1 (Example 2), Experimental Product 2 (Example 5), and Control Product (Comparative Example 1).
- the feeding method was to feed each infant according to the usual intake method, and the caregiver was surveyed and recorded at each feeding, using the digestive absorption index as the symptom that may appear in the infant according to the degree of digestion absorption. At this time, the digestive absorption index was the crying due to the constipation state, constipation, indigestion. Evaluation according to the results was evaluated as the degree of improvement of digestive absorption index compared to the control product (Comparative Example 1). The evaluation was very good compared to the control ( ⁇ ). Good levels ( ⁇ ), equivalent levels ( ⁇ ), and poor levels were evaluated as poor (X).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention concerne une composition de formule liquide pour nourrissons contenant du lait de chèvre et, plus spécifiquement, une composition de formule liquide pour nourrissons contenant au moins un élément choisi parmi le groupe constitué de lait, de lait en poudre, et de protéines dérivées de chèvres, sur la base du poids total de la caséine, la caséine αS1 étant contenue dans une plage de 0,1 à 27 % en poids et la β-caséine est contenue dans une plage de 40 à 80 % en poids. La composition de formule liquide pour nourrissons selon la présente invention présente d'excellents effets d'amélioration d'absorption digestive par les nourrissons et réduit des allergies par le biais d'un mélange respectueux du lait maternel contenant du lait de chèvre, et menant à un lait liquide pour nourrissons présentant une excellente stabilité significative dans le temps et une absorption digestive par l'intermédiaire du processus d'optimisation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680042883.XA CN107846914A (zh) | 2015-08-18 | 2016-08-12 | 含有山羊奶的液体调制乳组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0116254 | 2015-08-18 | ||
KR1020150116254A KR101640890B1 (ko) | 2015-08-18 | 2015-08-18 | 산양유를 함유한 액상 조제유 조성물 |
KR10-2016-0086860 | 2016-07-08 | ||
KR1020160086860A KR102050578B1 (ko) | 2016-07-08 | 2016-07-08 | 산양유를 함유한 액상 조제유 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017030330A1 true WO2017030330A1 (fr) | 2017-02-23 |
Family
ID=58050922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/008932 WO2017030330A1 (fr) | 2015-08-18 | 2016-08-12 | Composition de formule liquide pour nourrissons contenant du lait de chèvre |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN107846914A (fr) |
HK (1) | HK1252716A1 (fr) |
TW (1) | TWI703931B (fr) |
WO (1) | WO2017030330A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1026786B1 (nl) * | 2018-11-14 | 2020-06-16 | Inex Nv | Een groeimelk met verhoogde stabiliteit en een werkwijze voor het vervaardigen van de groeimelk |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1084868A (ja) * | 1996-09-12 | 1998-04-07 | Nisshin Flour Milling Co Ltd | 代用乳組成物およびその製造方法 |
JP3152977B2 (ja) * | 1991-12-02 | 2001-04-03 | 明治乳業株式会社 | 人乳に類似したカゼイン系蛋白質を含む乳蛋白質素材及びその製造方法 |
US20110281012A1 (en) * | 2007-04-16 | 2011-11-17 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
US20120040051A1 (en) * | 2010-08-13 | 2012-02-16 | Kwan-Han Chen | Process for preparing milk product enhanced with galactooligosaccharide and easily absorbable, and functional milk product prepared therewith |
KR20130123154A (ko) * | 2012-05-02 | 2013-11-12 | 주식회사 동원데어리푸드 | 원스테이지 균질을 통한 우유의 제조방법 |
KR101640890B1 (ko) * | 2015-08-18 | 2016-07-19 | 주식회사 엘지생활건강 | 산양유를 함유한 액상 조제유 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN201703762U (zh) * | 2010-04-29 | 2011-01-12 | 胡玉涛 | 一种乳品包装容器 |
CN102283289B (zh) * | 2011-09-15 | 2012-11-07 | 澳优乳业(中国)有限公司 | 一种不上火的婴幼儿配方奶粉及其制备工艺 |
KR101356926B1 (ko) * | 2012-02-13 | 2014-01-29 | 남양유업 주식회사 | 단백질 구성의 모유화로 소화력이 개선된 산양 영유아식 조성물 |
CN102835454A (zh) * | 2012-09-18 | 2012-12-26 | 张怀军 | 可在常温条件下长期保存的液态复原羊乳及其制备方法 |
CN103053694A (zh) * | 2013-02-18 | 2013-04-24 | 杨凌圣妃乳业有限公司 | 一种模拟母乳成分的婴幼儿羊奶粉及其制备方法 |
CN103070241B (zh) * | 2013-02-18 | 2014-08-27 | 杨凌圣妃乳业有限公司 | 一种纯羊乳蛋白婴幼儿配方羊奶粉及其制备方法 |
CN103392810A (zh) * | 2013-07-18 | 2013-11-20 | 河北国绿食生物科技有限公司 | 一种人乳化奶制品及其制备方法 |
-
2016
- 2016-08-12 WO PCT/KR2016/008932 patent/WO2017030330A1/fr active Application Filing
- 2016-08-12 CN CN201680042883.XA patent/CN107846914A/zh active Pending
- 2016-08-18 TW TW105126465A patent/TWI703931B/zh active
-
2018
- 2018-09-19 HK HK18112026.3A patent/HK1252716A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3152977B2 (ja) * | 1991-12-02 | 2001-04-03 | 明治乳業株式会社 | 人乳に類似したカゼイン系蛋白質を含む乳蛋白質素材及びその製造方法 |
JPH1084868A (ja) * | 1996-09-12 | 1998-04-07 | Nisshin Flour Milling Co Ltd | 代用乳組成物およびその製造方法 |
US20110281012A1 (en) * | 2007-04-16 | 2011-11-17 | Friesland Brands B.V. | Functional serum protein product for use in infant food and therapeutic compositions and methods for the preparation thereof |
US20120040051A1 (en) * | 2010-08-13 | 2012-02-16 | Kwan-Han Chen | Process for preparing milk product enhanced with galactooligosaccharide and easily absorbable, and functional milk product prepared therewith |
KR20130123154A (ko) * | 2012-05-02 | 2013-11-12 | 주식회사 동원데어리푸드 | 원스테이지 균질을 통한 우유의 제조방법 |
KR101640890B1 (ko) * | 2015-08-18 | 2016-07-19 | 주식회사 엘지생활건강 | 산양유를 함유한 액상 조제유 조성물 |
Also Published As
Publication number | Publication date |
---|---|
HK1252716A1 (zh) | 2019-05-31 |
TW201713217A (zh) | 2017-04-16 |
TWI703931B (zh) | 2020-09-11 |
CN107846914A (zh) | 2018-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ALKaisy et al. | Exploring the health benefits and functional properties of goat milk proteins | |
TWI301052B (en) | Infant formula compositions comprising increased amounts of alpha-lactalbumin | |
CN107156302A (zh) | 一种含乳脂肪球膜的婴幼儿配方奶粉及制备方法 | |
EP3945861B1 (fr) | Compositions nutritionnelles montrant une séparation de phase dans des conditions gastriques et leurs procédés de préparation | |
SE537951C2 (sv) | Profylaktisk användning av modersmjölksersättning mot otit | |
CN112056404A (zh) | 一种孕妇配方奶粉及其制备方法 | |
KR101356926B1 (ko) | 단백질 구성의 모유화로 소화력이 개선된 산양 영유아식 조성물 | |
WO2017030330A1 (fr) | Composition de formule liquide pour nourrissons contenant du lait de chèvre | |
EP3232820A1 (fr) | Nutrition de nourrisson avec des protéines hydrolysées, du calcium ionique et de l'acide palmitique | |
Muthusamy | Milk fat globular membrane: Composition, structure, isolation, technological significance and health benefits | |
KR101639676B1 (ko) | 액상 조제유 조성물 및 제조방법 | |
KR102050578B1 (ko) | 산양유를 함유한 액상 조제유 조성물 | |
RU2703172C2 (ru) | Питание для младенцев с гидролизованным белком и пальмитиновой кислотой | |
KR101640890B1 (ko) | 산양유를 함유한 액상 조제유 조성물 | |
KR101249082B1 (ko) | 유청분말과 혼합탈지분유의 가수분해물 및 베타카제인을 함유한 영유아용 조제유 조성물 및 조제유 | |
JP3223958B2 (ja) | 金属結合ラクトフェリン及びその用途 | |
KR102536585B1 (ko) | 액상 조제유 조성물 | |
KR101981606B1 (ko) | 액상 조제유 조성물 및 제조방법 | |
JPH11504201A (ja) | 粉砕卵殻で強化した乳製品 | |
Alnadari et al. | Immunomodulatory potential of bovine colostrum: a holistic perspective on health, disease resistance, and aging | |
WO1996029881A1 (fr) | Procede de production de preparations alimentaires pour prematures, nourrissons et d'aliments dietetiques | |
Kashyap | Ankit Kashyap, AK Santra, OP Dinani, Nishma Singh, Rupal Pahak, Subhrajit Das and Anupam Soni | |
CN115500398A (zh) | 富含β-酪蛋白配方乳制品及其制备方法 | |
KR20190084937A (ko) | 액상 조제유 조성물 및 제조방법 | |
CN114375999A (zh) | 富含κ-酪蛋白配方乳制品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16837272 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.07.2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16837272 Country of ref document: EP Kind code of ref document: A1 |